Core Insights - The company, Baiyin Biotechnology, focuses on the development of innovative biomaterials, leveraging high-throughput synthetic biology and artificial intelligence to create sustainable and low-cost solutions in the biomaterials sector [1] Group 1: Company Overview - Baiyin Biotechnology has successfully launched several core products, including recombinant mussel adhesive protein, Colamin sodium alginate, and fibronectin, gaining recognition from multiple Fortune 500 companies [1] - The company has completed nearly 300 million yuan in financing, with investments from notable institutions such as Wu Bo Lian Guang Pharmaceutical Fund and Wuyuan Capital, providing solid support for technological research and industrialization [1] Group 2: Product Innovation - The recombinant mussel adhesive protein, known as "marine soft gold," has significant value in wound care and medical aesthetics, but traditional production methods face challenges such as low yield and high resource consumption [2] - Baiyin Biotechnology has developed a green biomanufacturing system for recombinant mussel adhesive protein using synthetic biology, achieving the highest yield strains globally, which can replace billions of mussels in extraction [2] - The company has addressed application challenges such as compatibility and discoloration, creating multi-scenario solutions and establishing a robust intellectual property system to ensure product safety and stability [2] Group 3: Industry Impact - The project has established Baiyin Biotechnology as the first company in China to complete the medical device raw material filing for recombinant mussel adhesive protein and to lead the formulation of the first related group standard, filling a gap in the industry [2] - By March 2025, the company is expected to receive multiple medical device product registrations centered on recombinant mussel adhesive protein, launching a comprehensive series of products for wound care and mucosal repair [2] - The project transforms the traditional model reliant on natural resource extraction, setting a benchmark for "green alternatives to traditional methods," significantly reducing production costs and promoting the accessibility of high-performance biomaterials [2][3]

Core Viewpoint - The skincare brand Zhenyan Bio, which is preparing for an IPO on the Beijing Stock Exchange, has not kept pace with industry expansion despite its early entry into the market. The company has struggled to transition from a hospital-backed brand to a mainstream consumer brand, resulting in a significant gap in market presence and financial performance compared to leading competitors [1][9]. Financial Performance - Zhenyan Bio's revenue is projected to grow from 486 million yuan to 597 million yuan from 2023 to 2024, representing a year-on-year increase of approximately 22.8%. However, its net profit is expected to grow by only 7%, reaching 73 million yuan [2]. - In contrast, leading companies like Winona and Juzibio have already surpassed the 1 billion yuan revenue mark, indicating a structural gap in financial scale [2]. Market Share - Zhenyan Bio's market share in the skin barrier repair medical dressing market has remained below 4% from 2021 to 2023, failing to capitalize on the market's increasing fragmentation and heightened competition [2]. - While competitors like Juzibio and Fuyoujia have seen their market shares decline, Zhenyan Bio has not gained any significant market share during this period [2]. Channel Strategy - The company's sales system still reflects characteristics of an "in-hospital brand," with a high reliance on offline channels, including hospitals and OTC pharmacies, which accounted for 58.91% of total revenue in the past year [7]. - Zhenyan Bio has begun to adjust its channel structure, with the proportion of revenue from distribution decreasing to 44.88% as it shifts towards online direct sales and consignment [7]. Brand Positioning - Zhenyan Bio has launched sub-brands like "Zhenxiaoyan" for infant skincare and "Defilin" for bioactive compounds, but these attempts are still in the early stages and lack significant market presence [8]. - The company has not established a clear differentiation in product functionality, pricing, and brand positioning compared to competitors, limiting its ability to gain market traction [4][8]. Future Outlook - The company's challenges stem from its failure to upgrade its business model at critical stages, missing opportunities for channel transformation and brand amplification [9]. - The decision to pursue an IPO is seen as a strategy to secure time and resources for future transformation, although the window for catching up with competitors is narrowing [9].

Core Viewpoint - The article emphasizes the importance of developing a star ingredient in the Chinese market, where domestic brands are shifting from relying on traffic to building trust through self-researched key ingredients, focusing on precise care, high cost-effectiveness, and scientific backing [2][3][8]. Market Trends - The maturity of ingredient-focused consumers is leading to higher expectations for clinical validation, suitability for local skin types, and research history of ingredients [2]. - The traditional market logic of foreign brands, where "star ingredients equal strong brands," is being rewritten as domestic brands build cultural and technological confidence through rigorous research [3][8]. Brand Development - Domestic brands are focusing on creating "super brands" before developing star ingredients, which is crucial for their self-researched ingredients to gain prominence [6]. - The brand "Zhenyan" has established a strong professional image in the skincare market by integrating biotechnology and rigorous medical research, gaining recognition from over 500 dermatology professionals and being a top choice among clinical selections [6][8]. Ingredient Innovation - Zhenyan has successfully achieved large-scale production of recombinant mussel adhesive protein, overcoming previous challenges related to sourcing and environmental concerns [10][12]. - The unique properties of mussel adhesive protein, such as its high adhesion and film-forming capabilities, have been recognized in top scientific journals, establishing its efficacy in medical and academic circles [10][12]. Research and Development - Zhenyan has conducted over 1500 human efficacy validations for the recombinant mussel adhesive protein, confirming its rapid repair capabilities [12][15]. - The company has developed a comprehensive research and clinical verification system, collaborating with authoritative institutions to validate the efficacy of its products [15][17]. Market Performance - The Zhenyan Rapid Repair Essence, featuring recombinant mussel adhesive protein, has seen significant market success, selling over 16,000 bottles during the 2024 Double 11 shopping festival and achieving a 160% increase in sales during the 2025 618 event [27][29]. Strategic Positioning - Zhenyan is leveraging its technological breakthroughs to lead the market in the application of recombinant mussel adhesive protein, establishing itself as a leader in this emerging field [17][18]. - The brand's approach represents a strategic shift from marketing-driven to research-driven development, which is essential for long-term brand value and maturity in the domestic market [32].

Core Insights - Scientific communication has become a key element for brand development in the beauty industry, as consumer demand for skincare knowledge and product efficacy continues to grow [1] - The current state of scientific communication among beauty brands is inconsistent, with many brands struggling to effectively convey their scientific narratives, leading to a lack of innovation and reduced conversion efficiency [1] Group 1: Brand Positioning and Market Recognition - Zhenyan has established itself as a leading brand in the field of dermatological skincare since its inception in 2015, focusing on skin barrier repair [2] - The brand's unique approach is characterized by a strong medical research background, with the founding team having nearly 30 years of experience in the pharmaceutical industry, which informs their rigorous product development process [2] - Zhenyan ranked in the top three choices of dermatologists for clinical skincare products, highlighting its professional standing and market recognition [4] Group 2: Product Development and Scientific Rigor - Zhenyan employs a biopharmaceutical research mindset in its product development, adhering to strict pharmaceutical-grade standards throughout the entire process, from ingredient selection to efficacy validation [2][12] - The brand has developed a unique three-force model for skin barrier repair, integrating various high-quality protein components to provide comprehensive skin barrier restoration [28] - Zhenyan's core ingredient, recombined mussel adhesive protein, has shown significant clinical efficacy in repairing damaged skin barriers and alleviating sensitivity and redness, supported by numerous academic publications [30][34] Group 3: Collaboration and Academic Engagement - Zhenyan actively collaborates with hospitals and academic institutions to enhance its product offerings and ensure they meet clinical needs, thereby creating a complete loop of medical research and innovation [10][12] - The brand has participated in various national and regional dermatology conferences to share academic findings and promote industry development [10] - Zhenyan has launched several scientific publications and guidelines in collaboration with dermatologists, further solidifying its authority in post-aesthetic care [24] Group 4: Consumer Engagement and Education - Zhenyan has initiated various consumer engagement activities, including skin health consultations and educational campaigns, to promote its skincare philosophy and enhance consumer understanding of skincare [27] - The brand has developed its own scientific communication IPs to disseminate skincare knowledge through various media formats, making professional skincare concepts more accessible to consumers [27]

Core Insights - The skincare industry is experiencing intense competition in technology, with numerous suppliers showcasing unique ingredients and certifications at a recent cosmetics trade show [1][2][3] - The trend of emphasizing active ingredients and technical claims on product packaging is prevalent, as brands seek to carve out market positions by replicating successful commercial models [4][5] - The lack of authoritative industry standards and clarity on ingredient efficacy is causing confusion and skepticism among consumers [6][7][8] Group 1: Active Ingredients and Technology Trends - Active proteins and plant extracts remain core competitive areas in the skincare industry, with leading brands continuing to invest heavily in research and development [10][11] - The popularity of active proteins is driven by their previous applications in medical and aesthetic fields, which lend credibility to their use in consumer products [15][20] - New technologies in plant extraction are emerging, aiming to address traditional challenges such as stability and absorption rates [18][19] Group 2: Marketing and Industry Challenges - The rapid iteration of core ingredients in domestic beauty brands has outpaced normal industry evolution, leading to communication gaps between technology, products, and consumers [22][23] - The absence of unified national standards for new ingredients has resulted in market confusion and potential harm to consumers [24][26] - Overemphasis on marketing claims has led to exaggerated efficacy narratives, causing consumer dissatisfaction and adverse reactions [30][31][33] Group 3: Future Directions and Brand Strategies - The skincare industry is entering a period of deep adjustment, with competition shifting from ingredient-based to ecosystem-building capabilities [37][39] - Brands must find new competitive advantages beyond ingredient efficacy, such as emotional value and consumer experience [41][42] - The rise of niche markets, including male skincare and elderly care, presents new opportunities for growth and diversification [48][49]

Core Insights - The phenomenon of recombinant collagen has ignited enthusiasm in both the market and research sectors, indicating the imminent explosion of the functional protein field, particularly in beauty and skincare [1][2] - The market demand for skin repair products is rapidly increasing, positioning recombinant functional proteins for a golden development period [4][7] Group 1: Market Trends and Consumer Demand - The demand for skin repair products has reached unprecedented levels, with a reported 33.81% year-on-year increase in online discussions about repair products, and 52% of consumers becoming heavy users of sensitive skin repair products [7][9] - The beauty market has entered an era where "everyone needs repair," highlighting the necessity for effective skin repair solutions [9][30] Group 2: Company Innovations and Research - Zhenyan Biotech has developed over 100 self-researched core ingredients for medical device products, focusing on skin barrier repair through synthetic biology [4][6] - The company has established a multi-dimensional recombinant protein repair system, leveraging its decade-long experience to pave a forward-looking path for the functional protein industry [2][13] Group 3: Scientific Foundations and Clinical Validation - Zhenyan Biotech's core philosophy for skin repair is "health first, beauty second," breaking down skin barrier reconstruction into three forces: tolerance, repair, and restoration [11][30] - The company has published nearly 30 academic papers and holds 10 patents related to recombinant mussel adhesive protein, demonstrating its commitment to scientific research and clinical validation [16][19] Group 4: Product Development and Market Position - Zhenyan Biotech has successfully created a product matrix that includes skin disease auxiliary treatment and repair series, addressing diverse consumer needs [25][27] - The company has been recognized as a leader in the Chinese recombinant mussel adhesive protein skincare market, achieving the highest online reputation for three consecutive years [21][30] Group 5: Future Outlook and Strategic Positioning - The development momentum in skin barrier repair and recombinant functional proteins remains strong, with Zhenyan Biotech establishing a robust brand identity centered on "professional repair" [32] - The company's innovative approach in the functional protein sector not only builds a differentiated barrier for its brand but also illuminates a viable path for the high-quality development of the recombinant functional protein industry [32]